AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.008

0.000

Volume:3.98M

Turnover:29.65K

Market Cap:34.70M

PE:-0.45

High:0.008

Open:0.008

Low:0.007

Close:0.008

52wk High:0.040

52wk Low:0.007

Shares:4.34B

Float Shares:3.34B

Volume Ratio:0.21

T/O Rate:0.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-174.71%

ROA:-44.61%

PB:1.41

PE(LYR):-0.45

Loading ...

Overview Company News Filings

BRIEF-Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101

Radiopharm Theranostics Ltd - Rad and Siemens Sign Clinical Supply Agreement for Rad101

THOMSON REUTERS

Radiopharm Theranostics director Noel Donnelly files initial beneficial ownership statement

Radiopharm Theranostics files Form 3 for director Denise Hester Larkin

Radiopharm Theranostics Ltd: Doses First Patient in Phase 1 Clinical Study of Rad 402 in Advanced Prostate Cancer

THOMSON REUTERS

Radiopharm Theranostics Doses First Patient In Phase One Advanced Prostate Cancer Drug Candidate Trial

MT Newswires Live

$10,000 invested in this ASX healthcare share a year ago is now worth $36,500

Radiopharm Theranostics Achieves Primary Endpoint in 90% of Patients at Second Interim Analysis of Rad 101 Phase 2B Imaging Trial in Brain Metastases

THOMSON REUTERS

Radiopharm Theranostics Meets Primary Endpoint in 90% of Patients in Brain Imaging Trial

MT Newswires Live

Radiopharm Theranostics to present at NWR Virtual Healthcare Conference

Radiopharm Theranostics Ltd. Director Bruce Michael Goodwin Files Initial Beneficial Ownership Statement

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/RAD.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.008,"timestamp":1789539120000,"preClose":0.008,"halted":0,"volume":3982978,"delay":0,"changeRate":0,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4337549000,"eps":-0.0179,"marketStatus":"Not Yet Opened","change":0,"latestTime":"09-16 16:12:00 AEST","open":0.008,"high":0.008,"low":0.007,"amount":29651,"amplitude":0.125,"askPrice":0.008,"askSize":1455380,"bidPrice":0.007,"bidSize":6221721,"shortable":3,"etf":0,"ttmEps":-0.0179,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.008,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.209622,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.008,"auctionPrice":0.008,"auctionVolume":798548,"auction":3,"marketStatus":"盘后竞价","timestamp":1789538822869}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-44.61%","roe":"-174.71%","lyrEps":-0.0179,"volumeRatio":0.209622,"shares":4337549000,"dividePrice":0,"high":0.008,"amplitude":0.125,"preClose":0.008,"low":0.007,"week52Low":0.007,"pbRate":"1.41","psRate":"2.57","week52High":0.04,"institutionHeld":0,"latestPrice":0.008,"committee":0.620852,"eps":-0.0179,"divideRate":0,"volume":3982978,"delay":0,"ttmEps":-0.0179,"open":0.008,"prevYearClose":0.025,"prevWeekClose":0.008,"prevMonthClose":0.01,"prevQuarterClose":0.019,"fiveDayClose":0.009,"twentyDayClose":0.012,"sixtyDayClose":0.019,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625986839","title":"BRIEF-Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101","url":"https://stock-news.laohu8.com/highlight/detail?id=2625986839","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625986839?lang=en_us&edition=fundamental","pubTime":"2026-04-07 10:28","pubTimestamp":1775528920,"startTime":"0","endTime":"0","summary":"BRIEF-Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101April 7  - Radiopharm Theranostics Ltd RAD.AX:RAD AND SIEMENS SIGN CLINICAL SUPPLY AGREEMENT FOR RAD101SIEMENS HEALTHINEERS WILL RADIOLABEL, DISTRIBUTE RAD101 WITH FLUORINE-18 Further company coverage: RAD.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0MY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625607639","title":"Radiopharm Theranostics Ltd -  Rad and Siemens Sign Clinical Supply Agreement for Rad101","url":"https://stock-news.laohu8.com/highlight/detail?id=2625607639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625607639?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:31","pubTimestamp":1775514700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0MY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624261595","title":"Radiopharm Theranostics director Noel Donnelly files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624261595","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624261595?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:46","pubTimestamp":1775094416,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics director Noel Donnelly reported options to buy 8 million ordinary shares exercisable at AUD 0.06, with expirations through Sept. 30, 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL1w6z3s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624551776","title":"Radiopharm Theranostics files Form 3 for director Denise Hester Larkin","url":"https://stock-news.laohu8.com/highlight/detail?id=2624551776","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624551776?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:31","pubTimestamp":1774999904,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics director Denise Hester Larkin filed an initial Form 3 showing 644,247 ordinary shares held directly as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLc5HNrQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622829814","title":"Radiopharm Theranostics Ltd: Doses First Patient in Phase 1 Clinical Study of Rad 402 in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2622829814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622829814?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:10","pubTimestamp":1774613453,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F0P8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622736890","title":"Radiopharm Theranostics Doses First Patient In Phase One Advanced Prostate Cancer Drug Candidate Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2622736890","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622736890?lang=en_us&edition=fundamental","pubTime":"2026-03-27 08:22","pubTimestamp":1774570973,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  dosed the patient in its first-in-human phase one clinical trial of its RAD 402 drug candidate in advanced prostate cancer, according to a Friday Australian bourse filing.The trial is designed to study the safety, tolerability, whole-body distribution, and preliminary clinical activity of RAD 402 in patients with advanced prostate cancer, while the dose escalation phase one study is designed to determine the maximum tolerated dose and/or recommended phase two dose for expansion.RAD 402 is a monoclonal antibody targeting KLK3 radiolabelled with the radionuclide terbium 161.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0031619046.USD","IE00B66KJ199.SGD","BK7067","IE00B7SZL793.SGD","LU1815336091.USD","RAD.AU","AEIS","LU0757428866.USD","IE00B19Z4B17.USD","BK4157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622188031","title":"$10,000 invested in this ASX healthcare share a year ago is now worth $36,500","url":"https://stock-news.laohu8.com/highlight/detail?id=2622188031","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622188031?lang=en_us&edition=fundamental","pubTime":"2026-03-26 11:53","pubTimestamp":1774497205,"startTime":"0","endTime":"0","summary":"ASXhealthcare share Starpharma Holdings Ltd  has rocketed 365% over the past 12 months.Had you put $10,000 into this ASXsmall-capshare in March 2025, your holdings would be worth $36,500 today.These nanoscale molecules make medicines more effective in the body.Starpharma licenses its drug delivery technology to large pharma, and also develops its own anti-infection products.This ASX healthcare share is trading at 47 cents on Thursday, up 1.1%.What's behind the dramatic 365% share price rise?In September, the ASX healthcare share rose by more than 100% after the company announced two new partnerships.Starpharma signed a research and option agreement with Radiopharm Theranostics Ltd that made it eligible to receive a $500,000 option fee, a $2 million upfront payment, and up to $89 million in success-based payments and royalties on net sales.Is it too late to buy this rising ASX healthcare share?ASX biotech shares are notoriously risky and unsuitable for investors with a low risk toleranc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/26/10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/26/10000-invested-in-this-asx-healthcare-share-a-year-ago-is-now-worth-36500/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["VHT","BK7096","IXJ","BK4585","BK7508","BK4588","SPL.AU","BK7501","BK4550","RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621066404","title":"Radiopharm Theranostics Achieves Primary Endpoint in 90% of Patients at Second Interim Analysis of Rad 101 Phase 2B Imaging Trial in Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2621066404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621066404?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:01","pubTimestamp":1774350066,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40C02O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621344900","title":"Radiopharm Theranostics Meets Primary Endpoint in 90% of Patients in Brain Imaging Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621344900","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621344900?lang=en_us&edition=fundamental","pubTime":"2026-03-24 10:42","pubTimestamp":1774320161,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics'  second interim analysis from its phase 2b clinical imaging trial of RAD 101 in brain metastases showed that 90% of patients achieved concordance between positron emission tomography imaging and magnetic resonance imaging  for detecting brain metastases, achieving the primary endpoint, according to a Tuesday filing with the Australian bourse.RAD 101 is the company's small-molecule imaging agent targeting fatty acid synthase and radiolabeled with Fluorine-18 for the diagnosis of suspected recurrent brain metastases from various solid tumors, the filing said.The results indicated \"significant\" and selective tumor uptake in brain metastases, with images confirming metabolic activity compared with equivocal MRI scans.Additionally, the first five patients with evaluable six-month follow-up and biopsy data in the trial indicated a positive trend for sensitivity and specificity, per the filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620249687","title":"Radiopharm Theranostics to present at NWR Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620249687","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620249687?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:23","pubTimestamp":1773915795,"startTime":"0","endTime":"0","summary":"Radiopharm is scheduled to present at the NWR Virtual Healthcare Conference at 8:30am AEDT on 25 March 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbVRF9m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620256688","title":"Radiopharm Theranostics Ltd. Director Bruce Michael Goodwin Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620256688","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620256688?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:56","pubTimestamp":1773838603,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics reported an initial statement of beneficial ownership naming Bruce Michael Goodwin as a director. The filing stated that Bruce Michael Goodwin beneficially owned no securities of the company as of 03/18/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL8YD9hj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":71,"code":"91000000","status":"200"}]}}